Role of natural killer cell function in dendritic cell-based vaccines

References

• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 22(11), 633–640 (2001).
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann. Rev. Immunol. 19, 197–223 (2001).
   PubMed Web of Science ®Google Scholar
• Campbell KS, Colonna M. Human natural killer cell receptors and signal transduction. Int. Rev. Immunol. 20(3–4), 333–370 (2001).
   PubMedGoogle Scholar
• Glas R, Franksson L, Une C et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J. Exp. Med. 191(1), 129–138 (2001).
   Web of Science ®Google Scholar
• Mailliard RB, Son YI, Redlinger R et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. 171(5), 2366–2373 (2003).
   PubMed Web of Science ®Google Scholar
• Martin-Fontecha A, Thomsen LL, Brett S et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for T(H)1 priming. Nature Immunol. 5(12), 1260–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nature Rev. Immunol. 2(12), 957–964 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobs R, Hintzen G, Kemper A et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur. J. Immunol. 31(10), 3121–3127 (2001).
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T-cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101(8), 3052–3057 (2003).
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Caligiuri MA. Interleukin-15: biology and relevance to human disease. Blood 97(1), 14–32 (2001).
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T-cells in vivo in humans. Blood 100(1), 174–177 (2001).
   Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233–238 (2001).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann. Rev. Immunol. 21, 685–711 (2001).
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14(4), 420–431 (2002).
   PubMed Web of Science ®Google Scholar
• Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199(12), 1607–1618 (2004).
   PubMed Web of Science ®Google Scholar
• Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195(3), 327–333 (2002).
   Google Scholar
• Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195(3), 335–341 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate antitumor immune responses in vivo. Nature Med. 5(4), 405–411 (1999).
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Nishimura N, Suzuki Y, Sone S. Human monocyte-derived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur J. Immunol. 31(9), 2633–2641 (2001).
   PubMed Web of Science ®Google Scholar
• Yu Y, Hagihara M, Ando K et al. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J. Immunol. 166(3), 1590–1600 (2001).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195(3), 343–351 (2002).
   PubMed Web of Science ®Google Scholar
• Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 18, 245–273 (2000).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94(4), 459–473 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J. Immunol. 171(11), 5842–5852 (2003).
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T et al. A Phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 3(1), 9 (2005).
   Google Scholar
• Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol. Immunother. 5, 1–10 (2005).
   Google Scholar
• Riccardi C, Santoni A, Barlozzari T, Puccetti P, Herberman RB. In vivo natural reactivity of mice against tumor cells. Int. J. Cancer 25(4), 475–486 (1980).
   PubMed Web of Science ®Google Scholar
• Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J. Immunol. 131(2), 1024–1027 (1980).
   Google Scholar
• Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Cancer Immunol. Immunother. 319(6055), 675–678 (1986).
   Google Scholar
• Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 62(6), 1745–1759 (1985).
   Google Scholar
• Whiteside TL, Vujanovic NL, Herberman RB. Natural killer cells and tumor therapy. Curr. Top. Microbiol. Immunol. 230, 221–244 (1998).
   PubMed Web of Science ®Google Scholar
• Schantz SP, Ordonez NG. Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer. Nature Immun. Cell Growth Regul. 10(5), 278–288 (1991).
   PubMedGoogle Scholar
• Gonzalez FM, Vargas JA, Lopez-Cortijo C et al. Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch. Otolaryngol Head Neck Surg. 124(8), 852–856 (1998).
   PubMedGoogle Scholar
• Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer. 83(1), 58–63 (1998).
   PubMed Web of Science ®Google Scholar
• Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27(2), 194–203 (2000).
   PubMed Web of Science ®Google Scholar
• Semino C, Martini L, Queirolo P et al. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anticancer Res. 19(6C), 5645–5649 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85(8), 622–632 (1993).
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 76(12), 2421–2438 (1990).
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97(10), 3146–3151 (1990).
   Google Scholar
• Campbell JJ, Qin S, Unutmaz D et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166(11), 6477–6482 (2001).
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell receptors. Ann. Rev. Immunol. 16, 359–393 (1998).
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Alber SM, Shen H et al. IL-18-induced CD83+CCR7+ NK helper cells. J. Exp. Med. 202(7), 941–953 (2005).
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood 100(13), 4512–4520 (2002).
   PubMed Web of Science ®Google Scholar
• Munz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 105(1), 266–273 (2005).
   PubMed Web of Science ®Google Scholar
• Gerosa F, Gobbi A, Zorzi P et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. 174(2), 727–734 (2005).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA101(47), 16606–16611 (2004).
   PubMed Web of Science ®Google Scholar
• Nguyen KB, Salazar-Mather TP, Dalod MY et al. Co-ordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169(8), 4279–4287 (2002).
   PubMed Web of Science ®Google Scholar
• Granucci F, Feau S, Angeli V, Trottein F, Ricciardi-Castagnoli P. Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming. J. Immunol. 170(10), 5075–5081 (2003).
   PubMed Web of Science ®Google Scholar
• Vitale M, Della Chiesa M, Carlomagno S et al. NK-dependent DC maturation is mediated by TNF-α and IFN-γ released upon engagement of the NKp30 triggering receptor. Blood 106(2), 566–571 (2005).
   PubMed Web of Science ®Google Scholar
• Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunol. 4(2), 175–181 (2003).
   PubMed Web of Science ®Google Scholar
• Mocikat R, Braumuller H, Gumy A et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T-cell responses. Immunity 19(4), 561–569 (2003).
   PubMed Web of Science ®Google Scholar
• Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106(2), 609–616 (2005).
   PubMed Web of Science ®Google Scholar
• Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nature Immunol. 5(10), 996–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Buentke E, Heffler LC, Wilson JL et al. Natural killer and dendritic cell contact in lesional atopic dermatitis skin-Malassezia-influenced cell interaction. J. Invest. Dermatol. 119(4), 850–857 (2002).
   Google Scholar
• Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J. Leukoc. Biol. 72(5), 847–855 (2002).
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nature Rev. Immunol. 1(1), 41–49 (2001).
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J. Immunol. 173(10), 6418–6426 (2004).
   PubMed Web of Science ®Google Scholar
• Robinson E, Keystone EC, Schall TJ, Gillett N, Fish EN. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1β production by synovial T-cells. Clin. Exp. Immunol. 101(3), 398–407 (1995).
   PubMedGoogle Scholar
• Ferlazzo G, Thomas D, Lin SL et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172(3), 1455–1462 (2004).
   Google Scholar
• Freud AG, Becknell B, Roychowdhury S et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22(3), 295–304 (2005).
   PubMed Web of Science ®Google Scholar
• Borg C, Jalil A, Laderach D et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 104(10), 3267–3275 (2004).
   PubMed Web of Science ®Google Scholar
• Vitale M, Della Chiesa M, Carlomagno S et al. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-γ production upon interaction with dendritic cells. Eur. J. Immunol.34(6), 1715–1722 (2004).
   PubMed Web of Science ®Google Scholar
• Coudert JD, Coureau C, Guery JC. Preventing NK cell activation by donor dendritic cells enhances allospecific CD4 T-cell priming and promotes Th Type 2 responses to transplantation antigens. J. Immunol. 169(6), 2979–2987 (2002).
   PubMed Web of Science ®Google Scholar
• Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 33(6), 1657–1666 (2003).
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Screpanti V, Yagita H et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. 172(1), 123–129 (2004).
   PubMed Web of Science ®Google Scholar
• Kelly JM, Darcy PK, Markby JL et al. Induction of tumor-specific T-cell memory by NK cell-mediated tumor rejection. Nature Immunol. 3(1), 83–90 (2002).
   PubMed Web of Science ®Google Scholar
• Adam C, King S, Allgeier T et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106(1), 338–344 (2005).
   PubMed Web of Science ®Google Scholar
• Nieda M, Okai M, Tazbirkova A et al. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly co-ordinated secondary activation of acquired and innate immunity. Blood 103(2), 383–389 (2004).
   PubMed Web of Science ®Google Scholar